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Abstract
OBJECTIVE: To investigate the effects of artemis-
inin against proteinuria and glomerular filtration
barrier damage in rats with adriamycin-induced ne-
phropathy, and the potential mechanism under-
pinned the action.
METHODS: Forty adriamycin rats were randomly di-
vided into two groups with the ratio of 1︰3; the
small-number group served as control group (n=
10), and the rats in the large-number group were
treated with adriamycin to induce nephropathy;
then they were further randomly assigned into 3
subgroups: benazepril group (n=10), artemisinin
group (n=10), and adriamycin group (n=10). The
benazepril group and artemisinin group were treat-
ed with benazepril suspl (5.0 mg/kg daily) and arte-
misinin suspl (150 mg/kg daily) respectively after
being modeled; those in the control group and
adriamycin group were intragastrically adminis-
tered an equivalent volume of distilled water every
day. The treatment after model establishment last-
ed for a total of 4 weeks. The 24 h uric protein,
blood biochemicals, renal pathological changes, re-
nal ultrastrutural changes, Nephrin and Podocin
proteins and gene expressions were measured by
Coomassie brilliant blue assay, completely automat-
ic biochemical analyzer, light microscope, electron
microscopy, Western blot and reverse transcription
polymerase chain reaction, respectively.
RESULTS: The rats in adriamycin group showed a
significant increase in 24 h uric protein excretion,
serum total cholesterol (TC), triglyceride (TG),
blood urea nitrogen (BUN), serum creatinine (Scr)
and decrease in albumin (Alb) (P<0.05 or P<0.01).
Compared with adriamycin group, artemisinin
could reduce uric protein excretion, decrease the
serum TC, TG elevation, increase the serum Alb lev-
el, up-regulate the expressions of Nephrin and
Podocin (P<0.05 or P<0.01 ), but no statistical signif-
icance effects on the levels of BUN, Scr in artemis-
inin group (P>0.05). The renal pathological and ul-
trastrutural observation indicate that artemisinin
could attenuate the severity of foot process efface-
ment and fusion in the nephropathic rats.
CONCLUSION: Artemisinin might have an effect on
the nephropathy in rats caused by adriamycin,
which may be at least partly correlated with attenu-
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ation of the severity of foot process effacement and
fusion, up-regulation of the expressions of Nephrin
and Podocin in the glomeruli in the rats.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Proteinuria is an important risk factor for the progres-
sion and prognosis of chronic kidney disease (CKD),1
including minimal change nephropathy, focal segmen-
tal glomerular sclerosis, mesangial proliferative glomer-
ulonephritis, membranous nephropathy, diabetes melli-
tus, and lupus nephritis.2,3 Thus, the decreased urine
protein excretion level is associated with a slower deteri-
oration in renal function. Podocytes, a kind of highly
differentiated cells, forming multiple interdigitating
foot processes, are interconnected by the slit dia-
phragms (SD)4 and implicated in the development of
proteinuria.5 The genes that encode the podocyte-asso-
ciated proteins Nephrin and Podocin help maintain
the integrity of SD and prevent proteinuria.6 This sug-
gests that Nephrin and Podocin play important roles in
maintaining the structural and functional integrity of
the glomerular filtration barrier and the development
of proteinuria. At present, its treatment is more depen-
dent on glucocorticoid, and cytotoxicand neotype im-
munodepressive drugs etc. However, glucocorticoid re-
sistance and dependence, and their side effects are for-
midable problems. Therefore, novel therapeutic strate-
gies are necessary for a better clinical management of
the nephritic syndrome.
Artemisinin is a new type of sesquiterpene lactones
compound contained hydroperoxyradical group which
was extracted from artemisia annua L and A·apiacea
Hance by pharmaceutical workers of our country in
1971. It has the functions of immunological regula-
tion, anti-fibrosis, cell proliferation inhibition and
apoptosis inducement.7-10 In previous studies, we found
that artemisinin could reduce proteinuria/24 h, de-
crease the levels of TNF-α, IL-6 and down-regulate the
expression of the NF-kBp65 protein and NF-kB,
TGF-β1 mRNA in renal tissues.11 Theoretically, it is
possible that artemisinin could be used to treat other
kidney diseases. However, the therapeutic effect and
mechanisms are still unclear. The aims of the present
study are to investigate its protective effects on adriam-
ycin-induced nephropathy in rats' models, and to dis-
cuss the possible mechanism underlying the action.
MATERIALS ANDMETHODS
Animal
Forty healthy Male Sprague-Dawley rats of SPF grade,
eight-week-old, weighing (200 ± 20) g were purchased
from the Experimental Animal Center of Medical
School of Xi'an Jiaotong University (Certificate of qual-
ity No. 2008016). The experimental procedures were
approved by the Animal Ethics Committee of Medical
School of Xi'an Jiaotong University (Xi'an, China). All
animals were maintained in individual metabolic cages
in an air-conditioned room at a constant temperature
23℃±2℃ with a 12 h light/dark cycle, and allowed ad
libitum access to water and standard pelleted diet con-
taining 18% protein (w/w).
Drugs
Artemisinin (white to whitish needle crystalls or crystal
powder, 99%) was purchased from Xi'an Natural Field
Bio-technique Co., Ltd. (Xi'an, China), and benazepril
hydrochloride tablets (10 mg per tablet) from Beijing
Novartis Pharma Ltd. (Beijing, China).
Instruments and reagents
RA-1000 completely automatic biochemical analyser
was purchased from Amresco (Boston, MA, USA);
CX31 light microscope and HITACHI-600 transmis-
sion electron microscope was purchased from Nikon
(Tokyo, Japan); Q500IW image analysis system was
purchased from Leica (Dresden, Germany); Coomassie
brilliant blue assay was purchased from Amresco (Bos-
ton, MA, USA); TRIZOL reagent was purchased from
Invitrogen (Carlsbad, NM, USA); Lowry method (DC
Protein Assay, Biorad, Hercules, CA, USA).
Grouping, modeling and processing methods of the
animal
After 1 week of routine adaptive feed, all experiments
rats were randomly divided into two groups with the
ratio of 1∶3 by random number table method. Adriam-
ycin (7.5 mg/kg) was singly administered through the
tail vein of the rats in the large-number group (n=30)
to establish rats' models. An equivalent volume of nor-
mal saline was given to the rest as blank control group
(n=10). Seven days after the injection, 24 h urine sam-
ples were collected and the adriamycin-injected rats
were randomly divided into three subgroups (10 for
each) according to random number table. They were
adriamycin group, benazepril group, and artemisinin
group. The benazepril group and the artemisinin group
were administrated with benazepril suspl (5.0 mg/kg
daily) and artemisinin suspl (150 mg/kg daily) respec-
tively. Rats in the blank control group and adriamycin
group were intragastrically administered an equivalent
volume of distilled water every day. The treatment last-
ed for a total of 4 weeks.
24 h urine samples were collected to measure urinary
volume and urine protein level by using metabolic cag-
es on the 1th, 2th, 3th, 4th week. All rats were sacri-
ficed at the end of the experiment. The blood serum
was collected. Their kidneys were harvested, weighed,
and cut into portions for the examination with elec-
tron microscopy (EM) and light microscope, and for
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the preparation of glomerular protein and RNA. West-
ern blot and Semi quantitative RT-PCR were carried
out on glomerular protein and mRNA for Nephrin
and Podocin.
Experimental procedures
Measurement of uric protein: each animal was housed
separately in a metabolic cage to measure the 24 h uric
protein excretion, and the daily urine volume was mea-
sured. Uric protein was analyzed with Coomassie bril-
liant blue assay (Amresco, Boston, MA, USA).
Blood biochemical measurement: serum albumin
(Alb), Triglyceride (TG), total cholesterol (TC), blood
urea nitrogen (BUN) and serum creatinine (Scr) levels
were measured with a RA-1000 completely automatic
biochemical analyser (Boston, MA, USA).
Light microscope investigation: renal tissue samples
were put into 10% formaldehyde for fixation.
Three-micrometer thick paraffin histological sections
of the kidney cortex were observed and imaged under
light microscope (Pattern number: CX31, Nikon Com-
pany, Tokyo, Japan).
Transmission electron microscopy investigation: renal
tissue samples for electron microscopic assessment were
fixed in 2.5% glutaraldehyde in 0.1 mol/L phosphate
buffer (PB) for several days at 4℃. After washed in PB
and post-fixing in 1% OsO4 for 2 h, the fixed material
was dehydrated through an ethanolpropylene oxide se-
ries and embedded in Araldite M. The ultrathin sec-
tions were prepared and stained with uranyl acetate
and lead citrate, and then they were investigated and
photographed under a HITACHI-600 transmission
electron microscope (Tokyo, Japan).
Western blotting: the renal cortex and isolated glomer-
uli were homogenized in a Dounce homogenizer in RI-
PA buffer [consisting of 0.1% sodium dodecyl sulphate
(SDS), 1% TritonX-100, 150 mM NaCl, 1% sodium
deoxycholate and 10 mM ethylenediaminetetraacetic
acid [EDTA] in 25 mM Tris-HCl, pH7.2] and the pro-
tein concentrations of these samples were assayed by
the Lowry method (DC Protein Assay, Biorad, Hercu-
les, Santa Cruz, CA, USA). For SDS-polyacrylamide
gel electrophoresis (SDS-PAGE), samples were mixed
with an equal volume of sample buffer and boiled
for 5 min. Proteins (10 mg/lane) were run on 10%
polyacrylamide slab gels and transferred to polyvinyli-
dene fluoride membranes. The membranes were
blocked with 5% skimmed milk in PBS with 0.1%
Tween 20 for 1 h at room temperature and incubated
overnight with the primary antibodies (antibody con-
centrations were one-tenth of those used for IFM) at
4℃ . The membranes were then incubated with a
HRP-labeled goat anti-rabbit IgG. The bound second-
ary antibody was detected by enhanced chemilumines-
cence. Housekeeping protein β-actin was used as a
loading control. Positive immunoreactive bands were
quantified densitometrically (Leica Q500IW image
analysis system) and normalized for β-actin.
RNA extracting and RT-PCR: the renal cortex sam-
ples were flash-frozen in liquid nitrogen and stored
at ﹣80℃. The total RNA (1 μg) extracted from renal
cortex with TRIZOL (Invitrogen, Carlsbad, CA, USA)
was reverse-transcribed using superscript reverse tran-
scriptase to yield the respective cDNA. The efficiency
of the RT-PCR was controlled by glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) amplifica-
tion. Each sample mixture contained a standard PCR
buffer, 10-mM dNTP, 2 U Taq polymerase, and 5 pM
of each of the following primers: GAPDH, 5'-CAAG-
TTCAACGGCACAGTCAA-3'and 5'-TGGTGAAG-
ACGCCAGTAGACTC-3'; Nephrin, 5'-GGCGTAG-
CTTAGGGAC-3' and 5'-CCTAGCCGCCAATCAC-
3'; Podocin, 5'-CTAAGCAG TCTAGCTCATG-3' and
5'-CAATCACCCGCACTTT-3'; The PCR program
consisted of the following steps: 95℃ for 5 min; a de-
naturation step at 94℃ for 30 s; an annealing step at
52.3℃ (GAPDH), at 53.1℃ (Nephrin), at 54.1℃
(Podocin); and an extension step at 72℃ for 30 s, then
36 cycles for Nephrin and Podocin; 28 cycles for GAP-
DH; and a final extension at 72℃ for 7 min. The ex-
pected PCR product size was 596 bp for GAPDH,
299 bp for Nephrin, 392 bp for Podocin. The PCR
products were subjected to a computer-assisted densi-
tometry after electrophoresis on a 1% agarose gel and
staining with ethidium bromide.
Statistical analysis
The data were analyzed with SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA). The differences among the four
groups were tested using a one-way ANOVA with
SNK-q test. All values are expressed as the mean±SD,
and P<0.05 was considered statistically significant
RESULTS
24 h uric protein excretion
As shown in Table 1, during the observation period,
the rats in adriamycin group showed a marked increase
in 24 h uric protein excretion from the 1th week of the
experiment. After 4 weeks treatment, 24 h uric protein
excretion in the artemisinin and benazepril group was
less than that of the Adiamycin group, and there was
no significant difference between artemisinin group
and benazepril group.
Blood biochemicals change
As shown in Table 2, during the observation period,
the rats in adriamycin group showed a significant in-
crease in blood TG, TC, BUN, Scr and decrease in
Alb. After 4 weeks treatment, the serum levels of TG
and TC were lower and the serum Alb levels higher in
the benzaepril and arteminsin groups compared to the
adriamycin group, but there was no obviously change
in BUN and Scr levels in benzaepril and arteminsin
groups, and no significant difference between artemis-
inin group and benazepril group.
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Renal pathological changes
As shown in Figure 1, the rats in control group were
found to have normal glomerular structures, opened
glomerular capillary lumens, a smaller width of the me-
sangial region than that of the blood vessel diameter,
and normal renal tubule and interstitial substance. The
typical pathological manifestation of the rats in adriam-
ycin group was glomerular atrophy in part of the glom-
eruli. This was seen mainly as narrowing of the capil-
lary lumen, varying degrees of asymmetric mesangial
proliferation, and enlargement of the mesangial region
(the width of glomerular mesangial region is larger
than the diameter of the capillary). The rats in benaz-
epril group and artemisinin group had a smaller width
of the glomerularmesangial region and a relativelywider.
Renal ultrastrutural changes
As shown in Figure 2, electron microscopy investiga-
tions showed no podocyte shape changes, such as ede-
ma cytoplasm and foot process effacement in control
group (Figure 2A), there were foot process of GBM
widened, recoveried, and part of them fused and efface-
Group
Blank control
Adriamycin
Benazepril
Artemisinin
n
10
10
10
10
1th week
8.78±1.87a
62.02±11.22
52.55±12.87a
53.09±11.01a
2th week
8.78±1.87a
66.33±13.89
57.23±13.11a
50.13±10.12a
3th week
9.01±1.32a
90.12±15.79
75.55±17.26a
72.32±11.99a
4th week
8.56±1.35a
87.76±18.66
77.54±15.22a
70.69±13.99a
Table 1 24 h uric protein excretion (mg/24 h, xˉ ±s)
Notes: blank control and adriamycin group were administrated only with equivalent volume of distilled water every day; benazepril group
were administrated with benazepril suspl (5.0 mg/kg daily); artemisinin group were administrated with artemisinin suspl (150 mg/kg dai-
ly). aP<0.01, compared with the adriamycin group.
Group
Blank control
Adriamycin
Benazepril
Arteminsin
n
10
10
10
10
TG (mmol/L)
1.81±0.31a
4.63±1.55
3.12±1.66
1.98±0.42a
TC (mmol/L)
1.43±0.35a
3.84±1.08
2.78±1.21b
2.11±0.67b
Alb (g/L)
35.22±0.89b
31.59±1.60
32.99±1.97
34.78±0.66b
BUN (mmol/L)
5.42±0.58a
8.32±0.64
7.98±0.57
7.76±0.61
Scr (μmol/L)
27.30±6.11a
45.30±6.03
43.22±5.79
40.60±6.01
Table 2 Blood biochemicals change ( xˉ ±s)
Notes: blank control and adriamycin group were administrated only with equivalent volume of distilled water every day; benazepril group
were administrated with benazepril suspl (5.0 mg/kg daily); artemisinin group were administrated with artemisinin suspl (150 mg/kg dai-
ly). Alb: albumin; TG: triglyceride; TC: total cholesterol; BUN: blood urea nitrogen; Scr: serum creatinine. aP<0.01, bP<0.05, compared
with the adriamycin group.
Figure 1 Renal pathological changes (HE staining, ×400)
A: blank control group; B: adriamycin group; C: benazepril group; D: artemisinin group. Blank control and adriamycin group were
administrated only with equivalent volume of distilled water every day; benazepril group were administrated with benazepril
suspl (5.0 mg/kg daily); artemisinin group were administrated with artemisinin suspl (150 mg/kg daily). HE: hematoxylin and eo-
sin stain.
A B C D
Figure 2 Renal ultrastrutural changes (transmission electron microscopy; original magnification: ×10 000)
A: blank control group; B: adriamycin group; C: benazepril group; D: artemisinin group. Blank control and adriamycin group were
administrated only with equivalent volume of distilled water every day; benazepril group were administrated with benazepril
suspl (5.0 mg/kg daily); artemisinin group were administrated with artemisinin suspl (150 mg/kg daily).
A B C D
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ment. After 4 weeks treatment, Edema cytoplasm was
defluxioed and reduced obviously in adriamycin group
(Figure 2B), the pathological changes were improved,
and foot process structure was cleared in benazepril
group and artemisinin group (Figure 2C and D).
Expressions of Nephrin and Podocin proteins
Western blot analyses were performed for assessing
Nephrin and Podocin protein. As shown in Table 3
and Figure 3, the artemisinin treatment up-regulated
the protein expressions of Nephrin and Podocin (P<
0.01) in glomeruli, and there was no significant differ-
ence between the artemisinin group and benazepril
group.
Expressions of nephrin and podocin mRNA
Semi quantitative RT-PCR shown in Table 4 and Fig-
ure 4, the artemisinin treatment up-regulated the
mRNA expressions of Nephrin and Podocin (P<0.01)
in glomeruli, and there was no significant difference be-
tween the artemisinin group and benazepril group.
These results indicate that artemisinin on the levels of
mRNA expressions as the same effects as above the pro-
tein expressions.
DISCUSSION
Over the past decade, scientific research revealed that
podocyte injury was involved in many forms of glomer-
ular disease.12 Podocytes are highly differentiated cells
that have a limited ability to proliferate. A decrease in
podocyte number has been shown to accompany mas-
sive proteinuria in many forms of glomerular disease.
In addition, other researchers have found that a reduc-
tion in podocyte number results in the nudity of glo-
merular basement membrane (GBM) and, ultimately,
in focal segmental glomerulosclerosis (FSGS).13,14 This
suggests that FSGS is triggered by a decrease in podo-
cyte number to a certain extent.
Our study strived to address that artemisinin was able
to alleviate proteinuria and attenuate the severity of
foot process effacement and fusion in the adriamy-
cin-induced nephropathy rats with comparable thera-
peutic efficacy to benazepril. Biochemically, compared
with the rats in adriamycin group, the artemisinin treat-
ment alone decreased the TC and TG levels and in-
creased the serum Alb level in rats. These results indi-
cate that artemisinin might have an effect on lipid me-
tabolism.
Recent studies indicated that local podocyte damage
could induce injury in otherwise healthy podocytes
and further affect glomerular endothelial and mesan-
gial cells. This implies that even limited podocyte inju-
ry can initiate a vicious cycle of progressive glomerular
damage.15 Podocytes are composed of three parts of dif-
ferent structure and function, including cell body, car-
dinal processes, and foot processes. There are slit pores
among foot processes and the SD covering the slit
pores near the GBM forms the outer layer of the glo-
merular filtration barrier. The SD also plays a key role
Group
Control
Adriamycin
Benazepril
Artemisinin
n
10
10
10
10
Expression of
nephrin
0.341±0.032a
0.126±0.028
0.242±0.039a
0.264±0.027a
Expression of
podocin
0.363±0.029a
0.123±0.025
0.285±0.040a
0.291±0.039a
Notes: blank control and adriamycin group were administrated
only with equivalent volume of distilled water every day; benaz-
epril group were administrated with benazepril suspl (5.0 mg/kg
daily); artemisinin group were administrated with artemisinin
suspl (150 mg/kg daily). aP<0.01, compared with the adriamycin
group.
Table 3 Expressions of nephrin and podocin protein ( xˉ ±s)
Figure 3 The expressions of nephrin and podocin at protein
level
A: blank control group; B: adriamycin group; C: benazepril
group; D: artemisinin group. Blank control and adriamycin
group were administrated only with equivalent volume of
distilled water every day; benazepril group were adminis-
trated with benazepril suspl (5.0 mg/kg daily); artemisinin
group were administrated with artemisinin suspl (150 mg/
kg daily).
Nephrin
Podocin
β-actin
kDa
185
42
37
A B C D
Group
Control
Adriamycin
Benazepril
Artemisinin
n
10
10
10
10
Expression of
nephrin mRNA
1.18±0.12a
0.64±0.10
0.98±0.62a
1.12±0.61a
Expression of
podocin mRNA
1.25±0.14a
0.73±0.10
1.00±0.66a
1.17±0.11a
Table 4 Expressions of nephrin and podocin mRNA (OD val-
ue, xˉ ±s)
Figure 4 The expressions of nephrin and podocin at gene
level
A: blank control group; B: adriamycin group; C: benazepril
group; D: artemisinin group. Blank control and adriamycin
group were administrated only with equivalent volume of
distilled water every day; benazepril group were adminis-
trated with benazepril suspl (5.0 mg/kg daily); artemisinin
group were administrated with artemisinin suspl (150 mg/
kg daily). GAPDH: glyceraldehyde-3-phosphate dehydroge-
nase.
Nephrin
Podocin
GAPDH
kDa
299
392
596
A B C D
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in protein filtration.16 Nephrin is an important compos-
es of the SD and is fundamental in keeping the glomer-
ular filtration barrier function.17 Lately, some experi-
mental reports have shown that the anormal expression
of Nephrin leads to massive proteinuria.18,19 Podocin is
a membrane-associated protein of the band-7- stoma-
tin family that interacts with the cytosolic tail of Neph-
rin and connects Nephrin signalling to the cytoskele-
ton.20 In the proteinuric state, down-regulation and
shift localization of Podocin were observed.21 Nakhoul
et al 22 demonstrated in adriamycin rats that treatment
with the angiotension converting enzyme inhibitor
enalapril alone or in combination with losartan result-
ed in a significant preservation of Podocin. In the pres-
ent study, we observed that both artemisinin and bena-
zepril could modulate the protein and gene expressions
of Nephrin and Podocin at the end of the experiment.
The present study demonstrated that artemisinin could
decrease 24 h uric protein excretion and the serum lev-
els of TG and TC, and increase the serum Alb level.
The mechanism may be at least partly correlated with
attenuation of the severity of foot process effacement
and fusion, up-regulation of the protein and expres-
sions of Nephrin and Podocin in the glomeruli from
the modeled rats.
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